Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis.
Dr Jürg Zimmermann is the inventor of the drug imatinib (Gleevec(®), Glivec(®)), which entered the market in 2001 and revolutionized the treatment of chronic myelogenous leukemia. He talks to Future Medicinal Chemistry about his career as a medicinal chemist, current issues in pharmaceutical R&D and his experiences of developing Gleevec, the first protein kinase to get onto market.